In severe COVID-19-induced cytokine storm syndrome with organ failure, infliximab was reported to exert a rapid and at least temporary decrease in proinflammatory cytokines and other inflammatory markers (e.g., CRP and LDH) with clinical improvement [110,111]. This evidence concerns the gene CRP and COVID-19.